Clinical Study of Neoadjuvant Therapy With Apatinib and Paclitaxel in Local Advanced Triple-negative...
Triple Negative Breast CancerThe purpose of this study is to evaluate the efficacy and safety of apatinib in patient with TNBC
Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC
Triple Negative Breast NeoplasmsThis is a phase Ib/II Study of Leronlimab (PRO 140) combined with Carboplatin in Patients with CCR5+ Metastatic Triple Negative Breast Cancer (mTNBC). Study population will consist of patients with CCR5-positive, locally advanced or metastatic triple-negative breast cancer (mTNBC) who are naïve to chemotherapy in metastatic setting but have been exposed to anthracyclines and taxane in neoadjuvant and adjuvant settings (first-line).
A Multi-cohort Phase II Study of HER2-positive and Triple-negative Breast Cancer Brain Metastases....
Breast CancerThe study is being conducted to assess the effectiveness and safety of treatment options for breast cancer brain metastases based on molecular typing.
Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Capecitabine in the Treatment of Advanced...
Triple Negative Breast CancerNab-paclitaxelThis is a multi-center , open-lable clinical trial. Triple-negative breast cancer (TNBC) is a term applied to breast cancer cases that have <1% expression of the estrogen receptor (ER) and the progesterone receptor (PR) and do not over express HER2. TNBC is diagnosed in 15-20% of breast cancer cases and tends to occur in younger women and have biologically more aggressive high grade disease. The purpose of this study is to assess the efficacy and safety of the following two combinations: i) nab-paclitaxel+carboplatin; ii) nab-paclitaxel+capecitabine in subjects with advanced TNBC and up to one prior line of systemic treatment for metastatic disease. Maintenance therapy with capecitabine after completion of combination chemotherapy.
A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer
Triple-negative Breast CancerHX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the safety and preliminary efficacy of HX008+cisplatin+gemcitabine for the treatment of patients with metastatic triple-negative breast cancer will be evaluated.
A Phase Ⅱ Study of Anlotinib Combined With Tislelizumab and AT in the Neoadjuvant Treatment of Triple-negative...
Triple-negative Breast CancerThis is a prospective, single-arm and open-label phase II study, evaluating the efficacy and safety of anlotinib combined with tislelizumab and AT regimen as neoadjuvant treatment for triple-negative breast cancer. Participants will undergo/receive PDL1 testing after enrollment. All patients will be receive 6 cycles of low-dose anlotinib combined with tislelizumab and AT(Doxorubicin or Epirubicin+albumin-bound paclitaxel)regimen, followed by surgery.
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer...
Breast CancerBreast Diseases1 moreThis study will look at effects the combination of palbociclib and dose-dense neoadjuvant chemotherapy may have on triple negative breast cancer tumours which have not yet been treated.
Compare Apatinib Plus Capecitabine Versus Capecitabine in Maintenance Therapy for Patients With...
Triple-negative Breast CancerThe purpose of this study is to assess the efficacy and safety of patients who receive apatinib plus capecitabine or capecitabine for maintenance therapy of patients with with advanced triple-negative breast cancer
Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive...
Triple Negative Breast CancerEarly-stage Breast Cancer1 moreAn Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Neratinib Followed by Weekly Paclitaxel and Carboplatin Plus Neratinib in Early Stage Triple-Negative Breast Cancer Patients Who Exhibit Enhanced HER2 Signaling by Live Cell HER2 Signaling Transduction Analysis (FACT-2)
A Study of TQB2450 Injection and Anlotinib Hydrochloride Capsules to Treat Triple Negative Breast...
Triple Negative Breast Cancer (TNBC)The purpose of this study is to evaluate the efficacy and safety of PD-L1 inhibitorin in combination with Anlotinib treatment for patients with triple receptor negative breast cancer treated after failure of standard therapy (including Anthracyclines and/or Taxanes).